Patient Blood Management Market by Product (Instrument (Centrifuge, Transfusion Device, Apheresis, PCR, NGS, Storage Device), Accessories (Syringes, Vials), Reagents, Software)), Component, End User (Blood Bank, Hospital) - Global Forecast to 2024

“The patient blood management market is projected to reach USD 15.3 billion by 2024.”

The patient blood management market is projected to reach USD 15.3 billion by 2024 from USD 10.7 billion in 2019, at a CAGR of 7.4% from 2019 to 2024. The growth in this market is mainly driven by the rising number of blood donations and blood donors, surge in the prevalence of blood disorders, and rising awareness about blood transfusion safety. However, the high cost of automated instruments is expected to hinder their adoption among end users during the forecast period.

“Blood transfusion segment of instruments to register significant growth due to technological advancements.”
The product segment of the patient blood management market is segmented into instruments, accessories, reagents & kits, and software. The instrument segment is further sub-segmented into blood processing devices, blood transfusion devices, blood culture screening devices, diagnostic & testing instruments, and blood storage devices. Technological advancements, new product launches, coupled with the increasing use of autotransfusion systems during critical surgical procedures and organ transplantation, are expected to drive the growth of this segment in the near future.

“On the basis of component, the whole blood segment commanded the leading market share in 2018.”
In terms of components, the patient blood management market is segmented into whole blood and blood components. In 2018, the whole blood segment commanded a major share of the market due to the increasing number of blood donors and blood donations across the globe. Moreover, the increasing prevalence of blood disorders such as anemia and blood cancer that require whole-blood units and RBCs for blood transfusions will further increase the demand for whole blood units, thus contributing to the market growth.

“The US patient blood management market to hold a prominent market share during the forecast period.”
The patient blood management market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The US held the major share of the global patient blood management in 2018. Factors such as new product launches and technological advancements in patient blood management products and the presence of key players in this region are driving the growth of this market in the US. Moreover, favorable reimbursement guidelines and high awareness about blood transfusion safety will further fuel market growth.

Breakdown of supply-side primary interviews:
‧ By Company Type: Tier 1 - 45%, Tier 2 - 34%, and Tier 3 - 21%
‧ By Designation: C-level - 47%, Director-level - 33%, and Others - 20%
‧ By Region: North America- 35%, Europe - 32%, APAC - 25%, Latin America- 6%, and MEA - 2%

The major players in the market include Haemonetics Corporation (US), Fresenius SE & Co. KGaA (Germany), Terumo Corporation (Japan), Immucor, Inc. (US), B. Braun Melsungen AG (Ireland), Macopharma (US), bioMerieux SA (France), Asahi Kasei Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), Grifols, S.A. (Spain), F. Hoffmann-La Roche LTD (Switzerland), LivaNova PLC (UK), Danaher Corporation (US), Mediware Information Systems (US), Kawasumi Laboratories, Inc. (Japan), Haier Biomedical (China), Diatron (Hungary), and BAG Diagnostics GmbH (Germany), among others.

Research Coverage
This report studies the patient blood management market based on product, component, end user, and region. The report also studies factors such as drivers, restraints, opportunities, and challenges affecting market growth. It also provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to individual growth trends, and it also forecasts the revenue of the market segments with respect to five mainregions.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views. It also analyzes the competitive landscape; and high-growth countries along with their respective drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.1.1 SECONDARY DATA 25
2.1.1.1 Key data from secondary sources 26
2.1.2 PRIMARY DATA 26
2.1.2.1 Breakdown of primaries 27
2.1.2.2 Key data from primary sources 27
2.2 MARKET SIZE ESTIMATION 28
2.2.1 PRODUCT-BASED MARKET ESTIMATION 28
2.2.2 END USER-BASED MARKET ESTIMATION 29
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 31
2.4 ASSUMPTIONS FOR THE STUDY 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 36
4.1 PATIENT BLOOD MANAGEMENT MARKET OVERVIEW 36
4.2 PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT 37
4.3 PATIENT BLOOD MANAGEMENT MARKET, BY END USER 37
4.4 PATIENT BLOOD MANAGEMENT MARKET: REGIONAL GROWTH FORECASTS 38
5 MARKET OVERVIEW 39
5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
5.2.1 DRIVERS 40
5.2.1.1 Increasing demand for donated blood 40
5.2.1.2 Increasing number of blood donations and blood donors 41
5.2.1.3 Rising prevalence of target diseases 41
5.2.1.4 Regulatory guidelines for safe blood transfusion 42
5.2.1.5 Technological advancements in the patient blood management industry 44
5.2.2 RESTRAINTS 45
5.2.2.1 High cost associated with automated systems 45
5.2.3 OPPORTUNITIES 45
5.2.3.1 Market penetration opportunities in developing countries 45
5.2.3.2 Growing awareness regarding the safety of donated blood 46
6 PATIENT BLOOD MANAGEMENT MARKET, BY PRODUCT 47
6.1 INTRODUCTION 48
6.2 INSTRUMENTS 48
6.2.1 BLOOD PROCESSING DEVICES 49
6.2.1.1 Blood cell processors 50
6.2.1.1.1 Technological advancements in centrifugation systems might replace blood cell processors in the near future 50
6.2.1.2 Centrifuges 51
6.2.1.2.1 Longer lifespan of centrifuge systems to limit the growth of this segment 51
6.2.2 BLOOD TRANSFUSION DEVICES 52
6.2.2.1 Apheresis machines 53
6.2.2.1.1 Favorable reimbursement for therapeutic apheresis procedures to support market growth 53
6.2.2.2 Cell salvage systems 54
6.2.2.2.1 High cost of cell salvage systems as well as the dearth of trained professionals to restrain market growth 54
6.2.3 BLOOD CULTURE SCREENING DEVICES 55
6.2.3.1 Automated blood culture systems 56
6.2.3.1.1 Automated blood culture systems segment to witness higher growth during the forecast period 56
6.2.3.2 Supporting laboratory equipment 57
6.2.3.2.1 Growing automation to support the adoption of these equipment among end users 57
6.2.4 DIAGNOSTIC & TESTING INSTRUMENTS 57
6.2.4.1 PCR instruments 58
6.2.4.1.1 Significant adoption of RT-PCR to fuel market growth 58
6.2.4.2 Hematology analyzers 59
6.2.4.2.1 Technological advancements to support market growth 59
6.2.4.3 NGS platforms 60
6.2.4.3.1 RNA-Seq is an emerging approach for HIV testing 60
6.2.4.4 Blood grouping analyzers 61
6.2.4.4.1 Increasing adoption of blood grouping analyzers by blood banks to support market growth 61
6.2.4.5 Other instruments 62
?
6.2.5 BLOOD STORAGE DEVICES 63
6.2.5.1 Medical refrigerators 64
6.2.5.1.1 Medical refrigerators accounted for the largest share of the blood storage devices market in 2018 64
6.2.5.2 Medical freezers 64
6.2.5.2.1 Technological advancements to fuel market growth 64
6.3 ACCESSORIES 65
6.3.1 SYRINGES & NEEDLES 67
6.3.1.1 Easy availability and low cost of syringes and needles driving their adoption 67
6.3.2 VIALS & TUBES 67
6.3.2.1 Easier sample collection driving the adoption of vials and tubes 67
6.3.3 BLOOD BAGS 68
6.3.3.1 Increasing number of blood donations to support market growth 68
6.3.4 OTHER ACCESSORIES 69
6.4 REAGENTS AND KITS 69
6.4.1 BLOOD CULTURE MEDIA 71
6.4.1.1 A wide range of blood culture media are offered by companies 71
6.4.2 BLOOD TYPING REAGENTS 71
6.4.2.1 Mandatory use of ABO test prior to blood transfusion—A major factor supporting market growth 71
6.4.3 SLIDE STAINING REAGENTS 72
6.4.3.1 Rising applications of staining techniques to support market growth 72
6.4.4 ASSAY KITS 73
6.4.4.1 Growing adoption of NAT tests across the globe to support market growth 73
6.4.5 OTHER REAGENTS 74
6.5 SOFTWARE 75
6.5.1 BLOOD BANK AND TRANSFUSION MANAGEMENT SOFTWARE 76
6.5.1.1 This software segment to register the highest growth rate over the forecast period 76
6.5.2 OTHER SOFTWARE 77
7 PATIENT BLOOD MANAGEMENT MARKET, BY COMPONENT 78
7.1 INTRODUCTION 79
7.2 WHOLE BLOOD 79
7.2.1 GROWING DISEASE INCIDENCE AND RISING SURGICAL VOLUMES ARE DRIVING THE DEMAND FOR WHOLE BLOOD UNITS 79
7.3 BLOOD COMPONENTS 80
7.3.1 EXPANDING APPLICATIONS OF BLOOD PLASMA AND PLATELETS TO SUPPORT MARKET GROWTH 80
?
8 PATIENT BLOOD MANAGEMENT MARKET, BY END USER 82
8.1 INTRODUCTION 83
8.2 BLOOD BANKS 83
8.2.1 HIGH DEMAND FOR SAFE BLOOD IS DRIVING THE GROWTH OF THIS END-USER SEGMENT 83
8.3 HOSPITALS 84
8.3.1 LARGE VOLUME OF SURGICAL PROCEDURES PERFORMED IN HOSPITALS—MAJOR FACTOR DRIVING THE GROWTH OF THIS END-USER SEGMENT 84
9 PATIENT BLOOD MANAGEMENT MARKET, BY REGION 85
9.1 INTRODUCTION 86
9.2 NORTH AMERICA 87
9.2.1 US 90
9.2.1.1 The US dominates the patient blood management market due to the presence of well-developed healthcare infrastructure & growing adoption of advanced technologies 90
9.2.2 CANADA 92
9.2.2.1 Increasing number of surgical procedures performed in the country to drive the market for patient blood management products 92
9.3 EUROPE 95
9.3.1 GERMANY 98
9.3.1.1 Rising number of trauma cases and accidents to support market growth 98
9.3.2 UK 100
9.3.2.1 Rising number of road traffic accidents will support the growth of this market 100
9.3.3 FRANCE 102
9.3.3.1 Rising prevalence of blood disorders to support market growth in France 102
9.3.4 ITALY 104
9.3.4.1 Increasing awareness about safe blood transfusion will drive market growth 104
9.3.5 SPAIN 106
9.3.5.1 Government mandates to deliver safe blood for transfusion to support market growth 106
9.3.6 REST OF EUROPE 108
9.4 ASIA PACIFIC 110
9.4.1 JAPAN 114
9.4.1.1 Well-developed healthcare system and favorable reimbursement policy in the country to support market growth 114
9.4.2 CHINA 116
9.4.2.1 Market in China is estimated to grow at a high rate during the forecast period 116
9.4.3 INDIA 118
9.4.3.1 Favorable government initiatives to support market growth 118
9.4.4 AUSTRALIA 120
9.4.4.1 Presence of a highly developed healthcare system to contribute to market growth 120
9.4.5 SOUTH KOREA 122
9.4.5.1 Implementation of favorable government initiatives to support market growth 122
9.4.6 REST OF ASIA PACIFIC 124
9.5 LATIN AMERICA 126
9.5.1 BRAZIL 128
9.5.1.1 Growing medical tourism to support market growth in Brazil 128
9.5.2 MEXICO 130
9.5.2.1 Lack of awareness about blood donations to hamper market growth 130
9.5.3 REST OF LATIN AMERICA 132
9.6 MIDDLE EAST & AFRICA 134
10 COMPETITIVE LANDSCAPE 137
10.1 OVERVIEW 137
10.2 MARKET RANKING ANALYSIS, 2018 138
10.3 COMPETITIVE SCENARIO 139
10.3.1 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2017–2019) 139
10.3.2 PRODUCT LAUNCHES (2017–2019) 140
10.3.3 EXPANSIONS (2017–2019) 140
10.3.4 ACQUISITIONS (2017–2019) 140
10.4 COMPETITIVE LEADERSHIP MAPPING (2019) 141
10.4.1 VENDOR INCLUSION CRITERIA 141
10.4.2 VISIONARY LEADERS 141
10.4.3 INNOVATORS 141
10.4.4 DYNAMIC DIFFERENTIATORS 141
10.4.5 EMERGING COMPANIES 141
11 COMPANY PROFILES 143
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 ABBOTT LABORATORIES 143
11.2 ASAHI KASEI MEDICAL CO., LTD. (A SUBSIDIARY OF ASAHI KASEI CORPORATION) 146
11.3 B. BRAUN MELSUNGEN AG 148
11.4 BIOMERIEUX SA 150
11.5 BIO-RAD LABORATORIES, INC. 153
11.6 DANAHER CORPORATION 156
11.7 F. HOFFMANN-LA ROCHE LTD. 159
11.8 FRESENIUS SE & CO. KGAA 163
11.9 GRIFOLS, S.A. 166
11.10 HAEMONETICS CORPORATION 169
11.11 IMMUCOR, INC. 172
11.12 KANEKA CORPORATION 175
11.13 LIVANOVA PLC 177
11.14 MACOPHARMA 178
11.15 TERUMO CORPORATION 179
11.16 OTHER COMPANIES 183
11.16.1 MEDIWARE INFORMATION SYSTEMS 183
11.16.2 KAWASUMI LABORATORIES, INC. 184
11.16.3 HAIER BIOMEDICAL 185
11.16.4 DIATRON 186
11.16.5 BAG DIAGNOSTICS GMBH 187
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX 188
12.1 DISCUSSION GUIDE 188
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 193
12.3 AVAILABLE CUSTOMIZATIONS 195
12.4 RELATED REPORTS 195
12.5 AUTHOR DETAILS 196